# Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct04165590/  
OnCo record `nct04165590` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of an investigational treatment in advanced solid tumours, run by CAS Lamvac Biotech Co., Ltd., now recruiting.

## Summary

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT04165590 by CAS Lamvac Biotech Co., Ltd., with 60 participants planned, started 2019-10-24 and due to reach its primary completion in 2024-04-30.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04165590
- Phase: 1/2
- Setting: Clinical Study of Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
- Sponsor: CAS Lamvac Biotech Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04165590: https://clinicaltrials.gov/study/NCT04165590

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04165590.json